{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:49:27Z","timestamp":1790048967910,"version":"4.0.1"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.breast.2017.10.007","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T15:00:27Z","timestamp":1508770827000},"page":"28-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Therapeutic approaches for protecting bone health in patients with breast cancer"],"prefix":"10.1016","volume":"37","author":[{"given":"Diana","family":"L\u00fcftner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Niepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenther G.","family":"Steger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"45","key":"10.1016\/j.breast.2017.10.007_bib1","first-page":"1042","article-title":"Survival trends in European cancer patients diagnosed from 1988 to 1999","volume":"2009","author":"Verdecchia","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"51","key":"10.1016\/j.breast.2017.10.007_bib2","first-page":"2191","article-title":"Survival of women with cancers of breast and genital organs in Europe 1999\u20132007: results of the EUROCARE-5 study","volume":"2015","author":"Sant","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.breast.2017.10.007_bib3","series-title":"Cancer Research UK Breast cancer survival statistics","year":"2014"},{"issue":"Suppl 5","key":"10.1016\/j.breast.2017.10.007_bib4","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"10.1016\/j.breast.2017.10.007_bib5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.maturitas.2011.03.010","article-title":"Overview of long term care of breast cancer survivors","volume":"69","author":"Brennan","year":"2011","journal-title":"Maturitas"},{"key":"10.1016\/j.breast.2017.10.007_bib6","series-title":"National Cancer Institute SEER stat fact sheet: female breast cancer","year":"2011"},{"key":"10.1016\/j.breast.2017.10.007_bib7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/aje\/kwf049","article-title":"Natural history of bone loss over 6 years among premenopausal and early postmenopausal women","volume":"156","author":"Bainbridge","year":"2002","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.breast.2017.10.007_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bonekey.2015.60","article-title":"Cancer treatment-induced bone loss in women with breast cancer","volume":"4","author":"Hadji","year":"2015","journal-title":"BoneKEy Rep"},{"key":"10.1016\/j.breast.2017.10.007_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","article-title":"Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis","volume":"69","author":"Hadji","year":"2009","journal-title":"Crit Rev Oncology Hematol"},{"key":"10.1016\/j.breast.2017.10.007_bib10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1634\/theoncologist.2007-0152","article-title":"Cancer treatment-induced bone loss: pathophysiology and clinical perspectives","volume":"13","author":"Brufsky","year":"2008","journal-title":"The Oncologist"},{"key":"10.1016\/j.breast.2017.10.007_bib11","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.007_bib12","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","article-title":"A\u00a0high incidence of vertebral fracture in women with breast cancer","volume":"79","author":"Kanis","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2017.10.007_bib13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.breast.2017.10.007_bib14","series-title":"Amgen Prolia\u00ae summary of product characteristics","year":"2016"},{"key":"10.1016\/j.breast.2017.10.007_bib15","series-title":"Amgen Prolia\u00ae highlights of prescribing information","year":"2016"},{"key":"10.1016\/j.breast.2017.10.007_bib16","series-title":"Aclasta 5 mg solution for infusion summary of product characteristics","year":"2016"},{"key":"10.1016\/j.breast.2017.10.007_bib17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2017.10.007_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"10.1016\/j.breast.2017.10.007_bib19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MED.0b013e32834b4401","article-title":"Mechanisms and treatment of hypercalcemia of malignancy","volume":"18","author":"Clines","year":"2011","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.breast.2017.10.007_bib20","series-title":"Amgen XGEVA\u00ae highlights of prescribing information","year":"2016"},{"key":"10.1016\/j.breast.2017.10.007_bib21","series-title":"Novartis Europharm limited Zometa\u00ae summary of product characteristics","year":"2016"},{"key":"10.1016\/j.breast.2017.10.007_bib22","series-title":"Amgen Australia XGEVA\u00ae (denosumab) product information","year":"2016"},{"key":"10.1016\/j.breast.2017.10.007_bib23","first-page":"591","article-title":"Breast cancer metastasis: markers and models. Nature reviews","volume":"5","author":"Weigelt","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2017.10.007_bib24","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.breast.2017.10.007_bib25","article-title":"PCN20 Systematic review of skeletal related events in breast cancer","volume":"14","author":"Broder","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.breast.2017.10.007_bib26","series-title":"Amgen XGEVA\u00ae summary of product characteristics","year":"2016"},{"key":"10.1016\/j.breast.2017.10.007_bib27","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2017.10.007_bib28","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.007_bib29","first-page":"3497","article-title":"Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid","volume":"21","author":"von Moos","year":"2013","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"10.1016\/j.breast.2017.10.007_bib30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Med care"},{"key":"10.1016\/j.breast.2017.10.007_bib31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4329\/wjr.v7.i8.202","article-title":"Imaging of bone metastasis: an update","volume":"7","author":"O'Sullivan","year":"2015","journal-title":"World J Radiol"},{"key":"10.1016\/j.breast.2017.10.007_bib32","series-title":"EUROPA DONNA EUROPA DONNA and advocacy","year":"2016"},{"key":"10.1016\/j.breast.2017.10.007_bib33","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","author":"Baum","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2017.10.007_bib34","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.007_bib35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","article-title":"Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study","volume":"118","author":"Ellis","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2017.10.007_bib36","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2017.10.007_bib37","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1002\/cncr.29327","article-title":"5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial","volume":"121","author":"Wagner-Johnston","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2017.10.007_bib38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/14737140.2016.1192466","article-title":"Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis","volume":"16","author":"Abdel-Rahman","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.breast.2017.10.007_bib39","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Coleman","year":"2015","journal-title":"Lancet Lond Engl"},{"issue":"49","key":"10.1016\/j.breast.2017.10.007_bib40","first-page":"2086","article-title":"Oral adjuvant clodronate therapy could improve overall survival in early breast cancer: results from an updated systematic review and meta-analysis","volume":"2013","author":"Zhu","year":"1990","journal-title":"Eur J cancer Oxf Engl"},{"key":"10.1016\/j.breast.2017.10.007_bib41","first-page":"879","article-title":"Impact of skeletal complications on patients' quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"10.1016\/j.breast.2017.10.007_bib42","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS14-P5-16-03","article-title":"The impact of skeletal-related events on pain interference in patients with advanced breast cancer and bone metastases","volume":"75","author":"Fallowfield","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2017.10.007_bib43","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","article-title":"Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999\u20132007)","volume":"129","author":"Yong","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2017.10.007_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cncr.11859","article-title":"Is breast cancer survival improving?","volume":"100","author":"Giordano","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2017.10.007_bib45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2017.10.007_bib46","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/1471-2407-9-272","article-title":"Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity","volume":"9","author":"Major","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2017.10.007_bib47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.semnephrol.2003.08.015","article-title":"Hypercalcemia of malignancy","volume":"24","author":"Body","year":"2004","journal-title":"Seminars Nephrol"},{"key":"10.1016\/j.breast.2017.10.007_bib48","series-title":"Amgen Canada Inc XGEVA\u00ae (denosumab) product monograph","year":"2016"},{"key":"10.1016\/j.breast.2017.10.007_bib49","unstructured":"Amgen Russia XGEVA\u00ae (denosumab). Available from: http:\/\/www.amgen.ru\/products\/(Accessed 20 March 2017)."},{"key":"10.1016\/j.breast.2017.10.007_bib50","doi-asserted-by":"crossref","unstructured":"Curigliano G, Burstein HJ, E PW, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thurlimann B, St. Gallen International Expert Consensus on the Primary Therapy of Early Breast C, Andre F, Baselga J, Bergh J, Bonnefoi H, S YB, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ and Xu B De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals of oncology official journal of the European Society for Medical Oncology\/ESMO 2017;28:1700\u20131712.","DOI":"10.1093\/annonc\/mdx308"},{"key":"10.1016\/j.breast.2017.10.007_bib51","series-title":"Ibandronic acid summary of product characteristics","author":"Actavis UK Ltd","year":"2016"},{"key":"10.1016\/j.breast.2017.10.007_bib52","series-title":"Risedronate sodium (35 mg tablets)","author":"Sandoz Ltd","year":"2015"},{"key":"10.1016\/j.breast.2017.10.007_bib53","series-title":"Didronel PMO summary of product characteristics","author":"Warner Chilcott UK Ltd","year":"2006"},{"key":"10.1016\/j.breast.2017.10.007_bib54","series-title":"Ibandronic acid (3mg for injection) summary of product characteristics","author":"Actavis UK Ltd","year":"2016"},{"issue":"Suppl 3","key":"10.1016\/j.breast.2017.10.007_bib55","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"10.1016\/j.breast.2017.10.007_bib56","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel","volume":"27","author":"Hadji","year":"2016","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"10.1016\/j.breast.2017.10.007_bib57","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/annonc\/mdu385","article-title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)","volume":"25","author":"Cardoso","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"10.1016\/j.breast.2017.10.007_bib58","first-page":"151","article-title":"Prevention and treatment of bone metastases in breast cancer","volume":"2","author":"Ripamonti","year":"2013","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.breast.2017.10.007_bib59","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-014-2939-1","article-title":"A\u00a0phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease","volume":"145","author":"Coleman","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2017.10.007_bib60","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40265-014-0198-4","article-title":"Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases","volume":"74","author":"Shirley","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.breast.2017.10.007_bib61","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10147-012-0414-8","article-title":"Treatment of bone metastases before the onset of pain","volume":"18","author":"Costa","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.007_bib62","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.27789","article-title":"Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid","volume":"119","author":"Cleeland","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2017.10.007_bib63","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"10.1016\/j.breast.2017.10.007_bib64","article-title":"The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies \u2013 a European survey","volume":"26","author":"Lebret","year":"2017","journal-title":"Eur J Cancer Care"},{"issue":"51","key":"10.1016\/j.breast.2017.10.007_bib65","first-page":"1812","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"2015","author":"Body","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.breast.2017.10.007_bib66","first-page":"447","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"10.1016\/j.breast.2017.10.007_bib67","first-page":"524","article-title":"Impact of zoledronic acid on renal function in patients with cancer: clinical significance and development of a predictive model","volume":"4","author":"McDermott","year":"2006","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.breast.2017.10.007_bib68","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00198-011-1535-z","article-title":"GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int J Establ. Result Coop Between Eur Found Osteoporos Natl Osteoporos Found U. S. A"},{"key":"10.1016\/j.breast.2017.10.007_bib69","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/CIA.S2134","article-title":"Bisphosphonates in the management of postmenopausal osteoporosis \u2013 optimizing efficacy in clinical practice","volume":"3","author":"Bock","year":"2008","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.breast.2017.10.007_bib70","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/acr.21638","article-title":"Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.breast.2017.10.007_bib71","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00198-015-3164-4","article-title":"Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study","volume":"26","author":"Hadji","year":"2015","journal-title":"Osteoporos Int J Establ Result Coop Between Eur Found Osteoporos Natl Osteoporos Found U. S. A"},{"key":"10.1016\/j.breast.2017.10.007_bib72","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/00365590802475904","article-title":"Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines","volume":"43","author":"Ullen","year":"2009","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.breast.2017.10.007_bib73","first-page":"25","article-title":"The anti-tumour effects of zoledronic acid","volume":"3","author":"Zekri","year":"2014","journal-title":"J\u00a0Bone Oncol"},{"key":"10.1016\/j.breast.2017.10.007_bib74","first-page":"67","article-title":"RANK\/RANKL pathway in cancer: biological activity beyond bone?","volume":"1","author":"Pantano","year":"2012","journal-title":"J\u00a0Bone Oncol"},{"key":"10.1016\/j.breast.2017.10.007_bib75","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.0915148107","article-title":"Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland","volume":"107","author":"Beleut","year":"2010","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"10.1016\/j.breast.2017.10.007_bib76","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10549-014-2955-1","article-title":"RANK expression as a prognostic and predictive marker in breast cancer","volume":"145","author":"Pfitzner","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2017.10.007_bib77","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fonc.2013.00329","article-title":"Effects of RANKL-targeted therapy in immunity and cancer","volume":"3","author":"Cheng","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2017.10.007_bib78","first-page":"370","article-title":"Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma\/delta T cells","volume":"30","author":"Marten","year":"2007","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.breast.2017.10.007_bib79","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.breast.2017.10.007_bib80","article-title":"Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): an international, placebo-controlled, randomized, double-blind phase III clinical trial","volume":"31","author":"Goss","year":"2013","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.007_bib81","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.breast.2017.10.007_bib82","article-title":"Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG\/Alliance\/ECOG-ACRIN\/NCIC Clinical Trials Group\/NRG Oncology study S0307","volume":"33","author":"Gralow","year":"2015","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"64","key":"10.1016\/j.breast.2017.10.007_bib83","first-page":"12","article-title":"Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - the Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36\/ABCSG 29)","volume":"2016","author":"von Minckwitz","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.breast.2017.10.007_bib85","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.3892\/ol.2016.4977","article-title":"RANKL: a promising circulating marker for bone metastasis response","volume":"12","author":"Ibrahim","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.breast.2017.10.007_bib86","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1634\/theoncologist.2015-0527","article-title":"N-telopeptide of type I collagen long-term dynamics in breast cancer patients with bone metastases: clinical outcomes and influence of extraskeletal metastases","volume":"21","author":"Ferreira","year":"2016","journal-title":"The Oncologist"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977617305933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977617305933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:38:01Z","timestamp":1760776681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977617305933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":85,"alternative-id":["S0960977617305933"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2017.10.007","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic approaches for protecting bone health in patients with breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2017.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}